Re-shoring life sciences for a sustainable future

In partnership with HealthTech for Care, Forvis Mazars has carried out an in-depth study drawing on more than 20 interviews with leaders from pharmaceutical companies, medtechs, biotechs, CDMOs, investors and institutional experts. The research examines the practical conditions required to build a resilient European value chain. 

Download the study

Key insights

• Nearly 80%

  of pharmaceutical active ingredients used in Europe are imported from Asia 

• More than 60%

  of European biotechs struggle to finance their transition to industrialisation 

• On average, 18 months

  are needed to obtain CE certification for a medical device 

• Over €3 billion

  has been invested in flagship reshoring projects across Europe

• It can take up to 24 months

  to secure industrial land before permitting begins

• 20-30% higher

  combined payroll charges and property taxes on industrial sites in some EU countries, higher than neigbouring jurisdictions.

The findings reveal a sharp divide between political ambition and industrial reality. Complex regulation, limited access to industrial land and fragile economic models are slowing progress. At the same time, Europe’s advantages such as low-carbon energy, centres of excellence and high ESG standards remain underused. 

Innovation is flourishing, yet without adequate funding, breakthroughs in areas such as AI, continuous bioproduction and cell therapy risk moving abroad. 

Relocation is therefore both an industrial challenge and a public health imperative. By securing supply chains, reducing emissions and building resilience, Europe can guarantee patients faster, safer and more reliable access to life-saving treatments. 

Download the full study to explore the challenges, opportunities and strategic levers for a sustainable and sovereign healthcare industry in Europe.